Table 2.
Characteristics | Summary Statistics | Non-BL NHL (N = 32) |
Summary Statistics | Hodgkin Disease (N =
20) |
||||||
---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||||
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||
Age (years), median (range), per 1-year increase | 8 (1-19) | 0.95 (0.85-1.06) | .34 | 11 (7-14) | 1.05 (0.87-1.27) | .6 | ||||
Females, n (%); vs males | 10 (31.3) | 2.46 (0.87-7.00) | .09 | 31.66 (1.32-759.33) | .03 | 5 (25) | 2.02 (0.36-11.23) | .42 | ||
Histology, n (%) | 32 (100) | 20 (100) | ||||||||
Fever, n (%); vs no fever | 24 (75.0) | 10.36 (1.34-80.17) | .03 | 9.68 (0.31-298.90) | .2 | 11 (55.0) | 1.82 (0.33-9.99) | .49 | ||
Edema, n (%); vs no edema | 5 (15.6) | 3.12 (0.61-15.99) | .17 | 1 (5) | 5.82 (0.6-55.96) | .13 | ||||
Under weight for age, n (%) | 4 (23.5) | 3 (18.7) | 4.02 (0.65-24.82) | .13 | ||||||
HIV positive, n (%); vs HIV negative | 7 (21.8) | 2.04 (0.43-9.64) | .37 | 1 (5.0) | ||||||
Hb, median (IQR), per 1 g increase | 8.4 (7-10.3) | 0.82 (0.65-1.04) | .1 | 9 (5.6-10.5) | 0.59 (0.36-0.95) | .03 | ||||
Hb <8 g/dL, n(%); vs ≥8 g/dL | 14 (46.7) | 1.94 (0.63-5.96) | .25 | 8 (40) | 9.38 (1.09-80.66) | .04 | 6.22 (0.68-56.82) | .11 | ||
Plt <150 × 103/dL, n (%); vs ≥150 × 103/dL | 20 (69.0) | 2.68 (0.87-8.23) | .09 | 4.61 (0.22-94.98) | .32 | 15 (75) | 11.68 (1.89-72.03) | .01 | 6.82 (1.07-43.41) | .04 |
Late stage, n (%); late vs earlya | 26 (81) | 3.62 (0.48-27.61) | .2 | 1.33 (0.1-17.77) | .83 | 10 (50.0) | 1.21 (0.24-6.0) | .82 |
Abbreviations: non-BL NHL, non-Burkitt lymphoma non-Hodgkin lymphoma; HR, hazard ratio; CI, confidence interval; HIV, Human immune deficiency virus; IQR, interquartile range; Hb, hemoglobin level; Plt, platelet count.
Late-stage disease (stages III and IV); early-stage disease (stages III and IV).